本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
Extensive Production Service and Rental Offerings to Include: Cloud-based REMI, Remote Commentating, AI-driven Ingest and Clipping, and 5G Transmitters CUPERTINO, Calif., June 26, 2023 /PRNewswire/ -- TVU Networks, a pioneer in cloud-based workflow solutions for live content creation and distribution, is providing support for customers at the highly anticipated 2024 Summer Games taking place at 35 venues throughout France and Tahiti. As the world converges in the City of Light to witness this global sporting event, TVU will offer broadcasters and content creators the latest in cloud-based live video production tools and dedicated technical support both onsite and remotely. Summer Games 2024 TVU expects its cloud-based production solutions to be in especially high demand next summer by broadcasters. The company saw a more than 245% increase in total hours logged across its portfolio of cloud products during the time period of the most recent football competition in Qatar last year when compared to the total hours for the earlier Tokyo summer and Beijing winter games combined. Among the key offerings from TVU for the Summer Games will be its IP and cloud-based remote production ecosystem. TVU's solutions, including TVU RPS One for portable hybrid REMI, TVU Producer for professional cloud production, TVU RPS and TVU RPS Link Encoder for synchronized multi-camera IP remote production, TVU Remote Commentator for synchronized on-air audio commentaries, enable broadcasters to produce professional live content without the need for extensive on-site resources. Leveraging the cloud and a broadcaster's existing studio infrastructure, users can efficiently manage and control their productions remotely, ensuring high-quality coverage of the competition venues, athlete and fan interviews, beauty shots of France, and any breaking news while reducing costs and logistical complexities. These production tools will be available on a rental basis depending on the specific needs of the users. Broadcasters can also harness the power of TVU's AI-driven TVU Search to create even more compelling stories faster. TVU Search is a cloud-native, ingesting, indexing, search and clipping service designed to help storytellers quickly locate specific moments within large amounts of recorded and live video content fast using the power of artificial intelligence. You simply type in what you are looking for, and it rapidly finds content matching your description. For broadcasters looking to offer a dedicated channel covering all aspects of the Summer Games for their viewers, cloud-native TVU Channel offers a professional user-friendly service for creating, managing, and monetizing live programming channels across various platforms, including connected TV, OTA and OTT. Creators can use the content produced using tools from the TVU ecosystem or their own devices to quickly populate and launch programming channels with minimal costs and virtually no infrastructure. TVU Channel even seamlessly integrates with existing workflows, streamlining the entire broadcasting process. Continuing two decades of experience supporting events, TVU will provide equipment rentals of its award-winning TVU One 5G cellular transmitter in Paris as well as its full complement of IP and cloud-based remote production solutions. This rugged and proven device combines reliability, mobility, and high-quality video encoding capabilities, enabling broadcasters to transmit live video in 1080p or 4K HDR at sub-second latency. It uses aggregated cellular and patented IS+ technology to deliver exceptional resilience and efficiency. TVU will deploy a dedicated team of experts at the Summer Games. The onsite support team will be available before, during, and after the event to assist customers with equipment pickups, setup and technical questions. In addition to the onsite team, TVU will offer 24/7 remote technical support for the entire duration of the event. This round-the-clock support system is designed to give customers peace-of-mind that they can reach someone if any issues should arise, allowing them to focus on bringing all of the excitement of the games to their viewers. "TVU Networks is excited to be a part of next year's Summer Games and to support our customers in their coverage of this iconic global event," said Paul Shen, CEO, TVU Networks. "With our cloud-based remote production ecosystem, AI-driven TVU Search, and experienced equipment rental process, we are confident that broadcasters will have the tools they need to deliver captivating coverage onsite and remotely. Our dedicated technical support teams are committed to providing any assistance to our customers, ensuring their success throughout the event." Additional information about TVU's services for the Summer Games can be found at info.tvunetworks.com/summer-games-2024. About TVU Networks: TVU Networks is the premier global provider of SaaS and Cloud-based workflow solutions across multiple industries, including news, entertainment media, sports, corporate, streaming, houses of worship and government. Through the use of AI, microservices and automation-driven technology, TVU helps enterprises realize an efficient metadata and story-centric workflow through its ecosystem for live video acquisition, production and distribution. The company has been on the forefront of developing the tools needed to streamline and monetize the Media Supply Chain. TVU is a critical part of the operations of major media companies worldwide and is a Technology and Engineering Emmy® Award winner. Follow TVU Networks: LinkedIn: https://www.linkedin.com/company/tvu-networks/ Facebook: https://www.facebook.com/TVUNetworks/ Twitter: https://twitter.com/tvunetworks Instagram: https://www.instagram.com/tvu_networks/ YouTube: https://www.youtube.com/c/TVUNetworks Products Mentioned: TVU Anywhere: https://www.tvunetworks.com/products/tvu-anywhere/ TVU Channel: https://www.tvunetworks.com/products/tvu-channel-monetize/ TVU One: https://www.tvunetworks.com/products/tvu-one/ TVU Producer: https://www.tvunetworks.com/products/tvu-producer/ TVU Remote Commentator: https://www.tvunetworks.com/products/tvu-remote-commentator/ TVU RPS: https://www.tvunetworks.com/products/tvu-remote-production-system-rps/ TVU RPS One: https://www.tvunetworks.com/products/tvu-rps-one/ TVU Search: https://www.tvunetworks.com/products/tvu-search/
At 45-liters, ZEUS is the world's largest bottle of bubbly currently available BURGUNDY, France, June 26, 2023 /PRNewswire/ -- Luc Belaire has created the World's Largest Bottle of Bubbly*, dubbed "ZEUS," after the supreme ruler of the Greek gods. At 45 liters (the equivalent of 60 standard bottles of Belaire), Belaire ZEUS is the largest bottle of bubbly currently available. Its colossal form stands at more than one meter (3.5 feet) in height and weighs 72.5kg (160 pounds when full, requiring the strength of three people to carry and pour! Belaire ZEUS is a masterpiece of metalworking skill and creativity. The bottle was seven years in the making, crafted by aerospace engineers using a procedure never undertaken before: a process of spin forming, machining, internal coating, powder coating and pressure testing. Its steel form both insulates and protects the wine from extreme temperature and ensures Belaire ZEUS is nearly unbreakable! Extremely limited in production, only two bottles of Belaire ZEUS have been produced. One is filled with Belaire's signature Rare Rosé, a unique French sparkling wine which has become America's No.1 Rosé**. The second contains Luc Belaire Luxe, our smash hit demi sec; both are vinted at our winery in the heart of Burgundy. Each bottle of Belaire ZEUS contains an extraordinary three billion bubbles!*** Belaire's iconic bottles have, until now, been produced up to an impressive 15-liter size, known as a Nebuchadnezzar. The brand's large format bottles have become the go-to for celebrities, influencers, recording artists and athletes across the globe to celebrate career milestones, album launches and championship wins. With its towering form, ZEUS presents an extraordinary photo-op for fans - as such, both bottles will be undertaking a global tour! The tour will start in the U.S., where celebrities, creators and select fans will be invited to lift Belaire ZEUS via a bespoke pulley system, with a prize awarded to anyone strong enough to lift the massive bottle! You can expect to see Belaire ZEUS featured at events, sporting matches and in music videos. The tour's first stop will be at the Luc Belaire office in Manhattan, New York, where friends and fans will have the opportunity to be photographed next to this titanic wine bottle. NOTE TO MEDIA: Bottle Statistics: Bottle name: "Belaire ZEUS": the most powerful of all Greek Gods. Zeus was God of the sky and the king of Olympus Capacity: 45 liters, the equivalent of 60 standard bottles of Belaire Height: Over 1 meter or 40 inches Diameter: 29.21 centimeters, equivalent to 11.5 inches Circumference: 91.76 centimeters, equivalent to 36.12 inches Weight full: 160 pounds or 72.5kg Wine: Luc Belaire Rare Rosé and Luc Belaire Luxe Bubbles: Three billion bubbles in each bottle of Belaire ZEUS*** Follow @OfficialBelaire on social media and check out the Belaire ZEUS website for updates on Belaire ZEUS's tour and mammoth amounts of celebrity content. For more information and imagery contact: About Luc Belaire Luc Belaire is a premium brand produced in France – the hallmark of quality in the world of fine wines. Our 5th and 6th generation father-and-son winemakers oversee production of each bottle of Belaire at their Maison in Montagny-les-Beaune, established in 1898. The line includes Belaire Gold, made in Burgundy from a blend of Chardonnay and Pinot Noir, alongside Belaire's top-selling cuvée Belaire Rare Rosé, a unique sparkling Rosé crafted from a blend of Grenache, Cinsault and Syrah grapes – France's three favorite Rosé grapes – Belaire Luxe, an elegant 'blanc de blancs' made exclusively from Chardonnay, and Belaire Luxe Rosé, made from a classic blend of rosé varietals with a unique dosage. Finally, Belaire's Fantôme (French for "phantom") range houses each of its cuvées in a luminescent bottle which lights up at the touch of the button. The latest addition to the portfolio is Belaire Bleu, a limited-edition bottling with a spectacular sapphire color, inspired by the beautiful blue waters of France's Côte d'Azur. With stunning aromas of fresh berries and tropical fruits, Belaire Bleu is balanced with an elegant freshness and roundness which make this cuvée truly special. About Sovereign Brands Sovereign Brands is a family-owned, international wine & spirits company headquartered in the USA. The company is owned and operated by brothers Brett and Brian Berish. Sovereign has a portfolio of successful brands including Luc Belaire, a smash-hit line of French sparkling wines, which has earned global acclaim for its exquisite taste and striking packages and is available in more than 80 countries around the world. The company's portfolio also includes McQueen and the Violet Fog, an extraordinary gin from Jundiaí, Brazil, and Bumbu, a critically acclaimed line of rum products, and Villon, an exquisite French liqueur. Sovereign's newest release is the Deacon, a blended Scotch whisky. *By volume currently available **Nielsen, Market – TTL US XAOC + LIQUOR PLUS | Period – Latest 52 Weeks ending 05.20.23 | Subcategory – Sparkling Wine 750mls, 750ml EQ RTL > $20 | Measure - Units Sales *** Brandt, Linda. "How Many Bubbles Are in a Bottle of Champagne?" HeraldTribune.Com, 29 Dec. 2009, www.heraldtribune.com/story/news/2009/12/30/how-many-bubbles-are-in-a-bottle-of-champagne/28914141007/. At 45-liters, Belaire ZEUS is the world's largest bottle of bubbly currently available The making of Belaire ZEUS, the World’s Largest Bottle of Bubbly*Video link: https://youtu.be/WqzP6qpMydY Sizing up! The Luc Belaire range from the minute 187 ml Belaire Split to the enormous 45-liter Belaire ZEUS Luc Belaire’s opulent Belaire Luxe, made in Burgundy, in its smallest size – 187ml – and its largest – the 45-liter Belaire ZEUS
PETALING JAYA, Malaysia, June 26, 2023 /PRNewswire/ -- VISTA Eye Specialist (VISTA) has been recognized with the prestigious ESG Positive Impact Awards in Talent Management (Social Awards Category). The awards, presented by Star Media Group Berhad, acknowledges Malaysian companies that have effectively integrated environmental, social, and governance (ESG) principles into their business operation with the aim to accelerate the ESG momentum in Malaysia. Bernard Chan & Grace Heng receiving the award at the STAR ESG Postitive Impact Awards Gala Night. "We are deeply honored to receive the award for our efforts in developing and implementing effective and comprehensive training programs that empower talented individuals to contribute to our long-term success," stated Grace Heng, Chief Growth at VISTA. "This award is a testament to the dedication and hard work of our people, who have embraced our Gamification Upskilling Program, reflecting our commitment to making VISTA a company FOR its staff, in line with our core values." "Winning this ESG award not only boosts staff morale and engagement, but validates their contributions to the company's sustainability efforts, highlighting the positive impact they are making. This acknowledgment also creates a sense of pride and loyalty among employees, leading to increased motivation and retention" added Grace. Recognizing opportunities presented by the pandemic, VISTA introduced a unique Upskilling program incorporating Gamification principles and focusing on three key priorities: Growth, 10x Fun, Learning and Engagement, and WOW experience. This pioneering Gamification program incorporated competitive and enjoyable elements through various challenges and missions. "The successful completion of these challenges enabled staff to develop new ideas, acquire new skills, unleash their creativity and most importantly, cultivate leadership qualities," explained Bernard Chan, Training and Sustainability Manager at VISTA. The Gamification program, along with meticulously planned projects providing experiential learning and a training ground for emerging leaders, contributed to the development of numerous individuals who spearheaded substantial growth and had a notable impact not only on the staff but also on other stakeholders, including patients, laying a solid foundation for sustained success at VISTA. "Over the past two years, we have witnessed a three-fold increase in our growth rate compared to the previous eight-year average, a 32% rise in our workforce despite the pandemic, and the establishment of three new branches within a year. These achievements exemplify our commitment to contribute to the United Nations' Sustainable Development Goal 8, which promotes sustainable, inclusive, and robust economic growth, productive employment, and decent work for all," added Grace. "Winning this award reaffirms our determination to take our initiatives to the next level, extending beyond VISTA and encompassing community and environmental concerns. We aspire to make ESG an integral part of our company's DNA while motivating our staff to play a greater role in making a difference in issues that affect us all, ranging from suppliers and employees to customers and the world we inhabit," stated Bernard. About VISTA Eye Specialist: Established in 1999, VISTA is a prominent provider of eye care services in Malaysia, with 14 centers located across the country.
ROCKVILLE, Md. and SUZHOU, China, June 26, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, and RemeGen Co., Ltd. (688331.SH/09995.HK), today announced that they entered into a clinical trial collaboration and supply agreement with for the combination therapies of TYVYT® (sintilimab injection) with RC88, a novel mesothelin(MSLN)-targeting antibody-drug conjugate (ADC), or RC108, a novel c-Met-targeting ADC, respectively, as potential treatment options for advanced solid tumors in China. Under the agreement, Innovent will provide clinical drug supplies of TYVYT® (sintilimab injection) during the clinical trial collaboration. RemeGen will conduct Phase 1/2a clinical studies to evaluate the anti-tumor activity and safety of the combination therapy of TYVYT® (sintilimab injection) with RC88 or RC108 in Chinese patients with advanced solid tumors. TYVYT® (sintilimab injection) is an innovative PD-1 inhibitor co-developed by Innovent and Eli Lilly and Company. In China, sintilimab has been approved for seven indications and included in the National Reimbursement Drug List (NRDL) for six indications. TYVYT® (sintilimab injection) is the only PD-1 inhibitor for the first-line treatment of five high-incidence cancer types in the NRDL – including non-squamous NSCLC, squamous NSCLC, hepatocellular carcinoma, esophageal squamous cell carcinoma, and gastric cancer, as well as the first and the only immunotherapy medicine for gastric cancer in the NRDL. RC88 is a novel MSLN-targeting ADC independently developed by RemeGen. RC88 is currently being investigated in an ongoing Phase 1 clinical trial, which was approved by the NMPA in November 2018. The preliminary results demonstrated anti-tumor activity and a manageable safety profile of RC88 monotherapy in MSLN-positive advanced solid tumors. Preclinical studies also showed that RC88 can selectively delivers a potent cytotoxic payload to MSLN-expressing cells through internalization, thus inducing G2/M arrest and apoptosis. When combined with PD-1/PD-L1 or other immune checkpoint inhibitors (ICIs), RC88 can induce immunogenic cell death (ICD), releasing a series of signaling molecules to further activate T cells, enhance tumor immune response, and synergistically exert a stronger anti-tumor effect. RC108 is a novel c-Met targeting ADC independently developed by RemeGen. RC108 is currently being investigated in an ongoing Phase 1 clinical trial, which was approved by the NMPA in November 2020. The preliminary results demonstrated anti-tumor activity and a manageable safety profile of RC108 monotherapy in c-Met-positive advanced solid tumors. Preclinical studies also showed that RC108 can induce tumor-specific adaptive immunity and increase the infiltration of T cells into the tumor microenvironment, while anti-PD-1 monoclonal antibody can activate T cells to enhance anti-tumor killing effect. Therefore, it is expected that the combination therapy of RC108 and sintilimab can not only improve antigen presenting by dendritic cells , but also boost the tumor killing of T cells, therefore bringing in synergistic tumor inhibition effect. Dr. Hui Zhou, Senior Vice President of Innovent, stated: "We are pleased to collaborate with RemeGen to further explore the combination therapy potential of sintilimab injection and novel ADC candidates. Preclinical studies has suggested the synergistic anti-tumor effects, which supports the investigation of combining ADCs with an anti-PD-1 monoclonal antibody to improve patient outcomes and overcome drug-resistance. As immunotherapy advanced into next era of development, we hope to strengthen the leading position of sintilimab as a backbone immunotherapy as well as investigate the new opportunities of combination therapies, and provide better treatment options for more cancer patients. " Ms. Na Su, Senior Vice President of RemeGen, stated "Collaborating with Innovent is an important advancement in the research and commercialization strategy for the combination therapy of RC88 and RC108. The combination of RC88 and RC108 with sintilimab provides an innovative treatment approach that targets two different targets simultaneously. The mechanisms are complementary and synergistic, helping to overcome or delay resistance, achieve multi-pathway targeting of tumors, and provide an efficient solution for unmet clinical needs." About RC88 ADC RC88 is a novel anti-mesothelin ADC developed by RemeGen, which is formed by a recombinant humanized anti-MSLN monoclonal antibody conjugated to the microtubule inhibitor MMAE via a Linker. It includes an MSLN antibody moiety (also known as RC88 naked antibody), a linker, and a small molecule moiety of the cytotoxic pentapeptide MMAE. RC88 binds hMSLN with high affinity and specificity and can compete with endogenous ligands. It can kill tumor cells with different expression levels of MSLN, and the killing effect is positively correlated with the expression of MSLN. Functional studies on the Fc fragment showed that the Fc-mediated effect was not a major role in the effect of this drug. Based on promising preclinical data, a phase 1 study has been moving forward quickly. About RC108 ADC RC108 is a targeted antibody-drug conjugate (ADC) developed by RemeGen for the treatment of solid tumors with positive expression of the cell-matrix epithelial transition factor (c-MET). RC108 consists of a c-MET targeting antibody, a linker, and a small molecule cytotoxin. Its mechanism of action is similar to RC48, as it can selectively bind to c-MET-positive tumor cells, mediate antibody internalization, and effectively deliver the cytotoxin to cancer cells, achieving a good tumor-killing effect. In November 2020, RemeGen received approval from the National Medical Products Administration to conduct Phase 1 clinical trials of RC108 targeting c-MET-positive advanced solid tumors in China. The trial is currently progressing smoothly, and preliminary results show that RC108 has anti-tumor activity against c-MET-expressing solid tumors and is well-tolerated. In December 2022, RC108 obtained clinical trial permission from the U.S. Food and Drug Administration (FDA) to conduct clinical research in patients with c-MET-positive solid tumors. In April 2023, a combination therapy involving RC108 was approved to conduct Phase 1b/2 clinical research in China, targeting patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutations who have failed treatment with MET expression of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). Preclinical study results showed that RC108 induces tumor-specific adaptive immunity, increases T-cell infiltration into the tumor microenvironment, and PD-1 monoclonal antibodies activate T-cells, enhancing anti-tumor immune responses. Therefore, it is expected that the combination of RC108 and PD-1 antibodies can enhance dendritic cell presentation of tumor antigens and strengthen T-cell killing of tumor cells, resulting in an enhanced synergistic anti-tumor effect. About Sintilimab Sintilimab, marketed as TYVYT® (sintilimab injection) in China, is a PD-1 immunoglobulin G4 monoclonal antibody co-developed by Innovent and Eli Lilly and Company. Sintilimab is a type of immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1 / PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells[i]. Innovent is currently conducting more than 20 clinical studies of sintilimab to evaluate its safety and efficacy in a wide variety of cancer indications, including more than 10 registrational or pivotal clinical trials. In China, sintilimab has been approved for seven indications and included in the National Reimbursement Drug List (NRDL) for six indications. The updated NRDL reimbursement scope of TYVYT® (sintilimab injection) include: For the treatment of unresectable locally advanced, recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma; For the treatment of unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma; For the treatment of unresectable locally advanced or metastatic non-squamous non-small cell lung cancer lacking EGFR or ALK driver gene mutations; For the treatment of unresectable locally advanced or metastatic squamous non-small cell lung cancer; For the treatment of unresectable or metastatic hepatocellular carcinoma with no prior systematic treatment; For the treatment of relapsed or refractory classic Hodgkin's lymphoma after two lines or later of systemic chemotherapy. Additionally, sintilimab has been approved in combination with bevacizumab and chemotherapy (pemetrexed and cisplatin) for the treatment of patients with EGFR-mutated nsqNSCLC who progressed after EGFR-TKI therapy. Besides, two clinical studies of sintilimab have met their primary endpoints: Phase 2 study of sintilimab monotherapy as second-line treatment of esophageal squamous cell carcinoma; Phase 3 study of sintilimab monotherapy as second-line treatment for squamous NSCLC with disease progression following platinum-based chemotherapy. About Innovent Inspired by the spirit of "Start with Integrity, Succeed through Action," Innovent's mission is to develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people. Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines in the fields of oncology, metabolism, autoimmunity, ophthalmology and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK. Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 35 valuable assets in the fields of cancer, metabolic disorder, autoimmune disease and other major therapeutic areas, with 8 approved products on the market. These include: TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) , Pemazyre® (pemigatinib oral inhibitor), olverembatinib (BCR-ABL TKI) , Cyramza® (ramucirumab) and Retsevmo® (selpercatinib). An additional 3 assets are under NMPA NDA review, 6 assets are in Phase 3 or pivotal clinical trials, and 18 more molecules are in clinical studies. Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Roche, Sanofi, Adimab, Incyte, MD Anderson Cancer Center and other international partners. Innovent strives to work with many collaborators to help advance China's biopharmaceutical industry, improve drug availability and enhance the quality of the patients' lives. For more information, please visit: www.innoventbio.com. and www.linkedin.com/company/innovent-biologics/. Note: TYVYT® (sintilimab injection) is not an approved product in the United States. BYVASDA® (bevacizumab biosimilar injection), SULINNO®, and HALPRYZA® (rituximab biosimilar injection) are not approved products in the United States. TYVYT® (sintilimab injection, Innovent) BYVASDA® (bevacizumab biosimilar injection, Innovent) HALPRYZA® (rituximab biosimilar injection, Innovent) SULINNO® (adalimumab biosimilar injection, Innovent) Pemazyre® (pemigatinib oral inhibitor, Incyte Corporation). Pemazyre® was discovered by Incyte Corporation and licensed to Innovent for development and commercialization in Mainland China, Hong Kong, Macau and Taiwan. CYRAMZA® (ramucirumab, Eli Lilly). CYRAMZA® was discovered by Eli Lilly and licensed to Innovent for commercialization in Mainland China. Retsevmo® (Selpercatinib, Eli Lilly). Retsevmo® was discovered by Eli Lilly and licensed to Innovent for commercialization in Mainland China. Disclaimer: Innovent does not recommend any off-label usage. About RemeGen RemeGen Co., Ltd. (RemeGen) is a leading fully integrated biopharmaceutical company in China headquartered in Yantai, Shandong Province, China, and RemeGen has labs/offices in Beijing, Shanghai, California and Maryland. The company is committed to the discovery, development and commercialization of innovative and differentiated biologics for the treatment of autoimmune, oncology and ophthalmic diseases with unmet medical needs in China and globally. Currently, more than 20 biologics candidates are under development, and seven products with more than 20 indications are in clinical trials or have entered the commercialization stage. Among them, the first BLyS/APRIL dual-targeting fusion protein novel biologics globally for the treatment of SLE, Telitacicept was approved for marketing on March 9, 2021; and China's first domestically made antibody-drug conjugate Disitamab Vedotin was approved for marketing on June 8, 2021. RemeGen was listed on the Hong Kong Stock Exchange on November 9, 2020 (stock code: 09995.HK) and on the Science and Technology Board of the Shanghai Stock Exchange on March 31, 2022 (stock code: 688331.SH). Innovent's Forward-Looking Statements This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions. Reference [i] Wang J, Fei K, Jing H, et al. Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. mAbs 2019;11(8): 1443-1451.
公司獲得新型脂肽BRII-693的全球獨家權益，用於治療難治性多重耐藥/廣泛耐藥革蘭氏陰性菌感染 公司將返還Qpex Biopharma在大中華區的基於β-內酰胺酶抑制劑QPX7728的產品權益 公司將收到約2,400萬美元的首付款 中國北京和美國北卡羅來納州達勒姆2023年6月26日 /美通社/ -- 騰盛博藥生物科技有限公司（以下簡稱「騰盛博藥」或「公司」，股票代碼：2137.HK），一家致力於針對患者需求未被滿足的疾病開發治療方案，以改善患者健康狀況和治療選擇的生物技術公司，今天宣佈與Qpex Biopharma（「Qpex」）以及與收購Qpex的第三方Shionogi達成最終協議。 根據協議條款，騰盛博藥將獲得BRII-693（也稱為QPX9003）的全球獨家開發和商業化權益，以擴大其現有的大中華區權益。未來騰盛博藥無需再向Qpex支付與BRII-693相關的成本分攤費用、里程碑費用和特許權使用費。公司將返還基於QPX7728的產品BRII-636和BRII-672在大中華區的獨家權益，並不再向Qpex支付與這些產品相關的成本分攤費用、里程碑費用和特許權使用費。 與此同時，Qpex將完成與Shionogi的合併。作為Qpex的股東以及QPX7728大中華區權益的轉讓方，騰盛博藥在收購完成後將獲得約2,400萬美元的收入，以及未來基於在美國的里程碑事件的潛在付款。 BRII-693是一種處於研發階段的新型合成脂肽，用於治療多重耐藥/廣泛耐藥（MDR/XDR）革蘭氏陰性菌感染的危重症患者，特別是耐碳青霉烯類鮑曼不動桿菌和耐碳青霉烯類銅綠假單胞菌感染。2019年10月，騰盛博藥與Qpex簽訂了許可協議，獲得了BRII-693和基於QPX7728的產品在大中華區的開發和商業化權益。 騰盛博藥董事長兼首席執行官洪志博士表示：「BRII-693由於具有明確的抗菌機制和更優良的安全性，有望成為治療革蘭氏陰性菌感染危重症患者的最安全和最有效的多粘菌素。同時鑒於BRII-693的微生物學和臨床特徵，我們非常高興有機會優先專注該藥物的全球開發。」 2023年4月，騰盛博藥向中國藥品監督管理局（NMPA）提交了在中國開發BRII-693（QPX9003）的新藥臨床試驗（IND）前申請。 關於BRII-693 BRII-693是在澳大利亞莫納什大學生物醫學發現研究所李健教授的指導下發現的一種新型抗菌脂肽。這一發現得到了美國國家過敏和傳染病研究所（NIAID；RO1 AI098771和AI132154）的部分資助。BRII-693的發現和臨床前研究於2022年發表於《Nature Communications》雜誌。研究結果表明，與之前的多粘菌素抗菌劑相比，BRII-693的效果更好，且毒性較小。與目前可用的多粘菌素抗生素相比，BRII-693可改善腎臟安全性，對治療革蘭氏陰性菌感染，包括MDR/XDR菌株的治療取得了重大進展。 2021年，QPX9003（BRII-693）獲得美國藥品監督管理局（FDA）授予的「合格傳染病產品資格」（QIDP）認定。QIDP認定為BRII-693在美國的研發提供了政策激勵，包括獲得優先審評和FDA快速通道認定資格，同時也可能延長在美國的監管和市場排他期。 2022年10月，在華盛頓特區舉辦的美國感染性疾病周（IDWeek）上公佈的在美國進行的首次人體臨床研究的1期中期結果表明，BRII-693在所有試驗劑量下均安全且耐受性良好。2022年12月，與美國FDA召開了1期結束會議，並與其討論了這些結果以及未來3期項目的方案。 關於騰盛博藥 騰盛博藥（股票代碼：2137.HK）是一家生物技術公司，致力於針對存在巨大未被滿足的患者需求、治療手段有限，以及給患者帶來嚴重社會病恥感的世界最常見的疾病開發創新療法。公司專注於傳染性疾病和中樞神經系統疾病，正在推進一條涵蓋多種獨特候選藥物的產品管線，並通過領先的項目開發針對乙型肝炎病毒（HBV）感染的新型功能性治癒方案，和針對產後抑鬱症（PPD）的首創治療方案。在富有遠見卓識和經驗豐富的領導團隊帶領下，公司在位於羅利-達勒姆、舊金山灣區、北京和上海的主要生物技術中心開展業務。欲瞭解更多信息，請訪問www.briibio.com。
Company acquires exclusive global rights of the novel lipopeptide BRII-693 for the difficult to treat MDR/XDR gram-negative bacterial infections Company returns Greater China rights to Qpex Biopharma of beta-lactamase inhibitor QPX7728-based products Company to receive ~$24M upfront cash payments DURHAM, N.C. and BEIJING, June 25, 2023 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs, today announced that it entered into definitive agreements with Qpex Biopharma ("Qpex") and third parties in connection with the acquisition of Qpex by Shionogi. Under the terms of the agreement, Brii Bio will acquire exclusive global rights for the development and commercialization of BRII-693 (also known as QPX9003) to expand from its existing rights in Greater China. All existing cost-share, milestone and royalty payments associated with BRII-693 to Qpex are eliminated. The Company will return its exclusive rights to QPX7728-based products BRII-636 and BRII-672 in Greater China to Qpex and Brii will no longer be responsible for cost-share, milestone and royalty payments to Qpex associated with these products. In association with the return of QPX7728-based program rights to Qpex, Qpex will complete a merger through acquisition by Shionogi. Brii Bio will receive approximately $24 million upon closing of the acquisition as a Qpex shareholder and the return of the QPX7728 product rights, with potential contingency payments for future milestone events in the US. BRII-693 is a novel synthetic lipopeptide in development for the treatment of critically ill patients with MDR/XDR gram-negative bacterial infections, especially carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. In October 2019, Brii Bio entered into a licensing agreement with Qpex to develop and commercialize BRII-693 and the QPX7728-based products in Greater China. "With the demonstrated antibacterial mechanism and improved safety profile, BRII-693 has the potential to be the safest and most effective polymyxin for the treatment of critically ill patients with gram-negative bacterial infections," said Zhi Hong, Ph.D., Chairman and Chief Executive Officer of Brii Bio, "Given the microbiological and clinical profile of BRII-693, we are very excited about this opportunity to prioritize and focus on the global development of this agent." In April 2023, Brii Bio submitted a pre-IND to the National Medical Products Administration (NMPA) for the development of BRII-693 (QPX9003) in China. About BRII-693BRII-693 is a novel lipopeptide antimicrobial that was discovered under the directions of Professor Jian Li of the Biomedicine Drug Discovery Institute of Monash University in Australia. BRII-693's discovery was supported in part by funds from the U.S. National Institutes of Allergy and Infectious Diseases (NIAID; RO1 AI098771 and AI132154). The discovery of BRII-693 and preclinical studies were described in 2022 in the journal Nature Communications and show improved potency and less toxicity compared to older polymyxin antimicrobial agents. BRII-693 has the potential to be an important advance in the treatment of gram-negative infections, including MDR/XDR strains, with improved renal safety compared to currently available polymyxin antibiotics. In 2021, the US FDA designated QPX-9003 (BRII-693) to be a Qualified Infectious Disease Product (QIDP). The QIDP designation provides incentives for the development of BRII-693 in the US, including priority review and eligibility for FDA's Fast Track Designation; there is also the potential for extension of regulatory and market exclusivity in the US. In October 2022, the interim Phase 1 results from a completed first-in-human clinical study conducted in the US presented at ID Week in Washington DC demonstrated that BRII-693 is safe and well-tolerated at all doses tested. An end of Phase 1 meeting was convened with the US FDA in December 2022 and these results along with approaches for a future Phase 3 program were discussed with the agency. About Brii BioBrii Biosciences ("Brii Bio", stock code: 2137.HK) is a biotechnology company developing therapies to address some of the world's most common diseases where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious and central nervous system diseases, the Company is advancing a broad pipeline of unique therapeutic candidates with lead programs to develop a novel functional cure for hepatitis B viral infection (HBV) and a first-of-its-kind treatment for postpartum depression (PPD). The Company is led by a visionary and experienced leadership team and has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. For more information, visit www.briibio.com.
A12 藝術空間
new
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
